0001209191-21-068000.txt : 20211203 0001209191-21-068000.hdr.sgml : 20211203 20211203191921 ACCESSION NUMBER: 0001209191-21-068000 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211201 FILED AS OF DATE: 20211203 DATE AS OF CHANGE: 20211203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blackman Samuel C. CENTRAL INDEX KEY: 0001863676 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40431 FILM NUMBER: 211471598 MAIL ADDRESS: STREET 1: 395 OYSTER POINT BLVD. STREET 2: SUITE 217 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Day One Biopharmaceuticals, Inc. CENTRAL INDEX KEY: 0001845337 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832415215 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 395 OYSTER POINT BLVD STE 217 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080-1930 BUSINESS PHONE: 206-913-4300 MAIL ADDRESS: STREET 1: 395 OYSTER POINT BLVD STE 217 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080-1930 FORMER COMPANY: FORMER CONFORMED NAME: Day One Biopharmaceuticals Holding Co LLC DATE OF NAME CHANGE: 20210209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-12-01 0 0001845337 Day One Biopharmaceuticals, Inc. DAWN 0001863676 Blackman Samuel C. 395 OYSTER POINT BLVD, SUITE 217 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer Common Stock 2021-10-22 5 G 0 E 1000000 0.00 D 1386718 D Common Stock 2021-10-22 5 G 0 E 1000000 0.00 A 1000000 I By the 2021 Blackman Family LLC Common Stock 2021-12-01 4 S 0 5089 16.6224 D 1381629 D Common Stock 2021-12-01 4 S 0 4502 17.8119 D 1377127 D Common Stock 2021-12-01 4 S 0 409 18.2435 D 1376718 D On October 22, 2021, the Reporting Person contributed 1,000,000 shares of the Issuer's Common Stock to the 2021 Blackman Family LLC (the "Trust"), of which the Reporting Person is the sole manager, and has shared voting and dispositive power with his wife as members. The Reporting Person continues to report beneficial ownership of all of the Issuer's Common Stock held by the Trust but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest therein. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.19 to $17.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $18.18 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.22 to $18.29 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Charles N. York II, as Attorney-in-Fact 2021-12-03